Compare FMN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMN | ACRV |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 74.0M |
| IPO Year | N/A | 2022 |
| Metric | FMN | ACRV |
|---|---|---|
| Price | $11.09 | $2.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 23.8K | ★ 382.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.56 | $1.27 |
| 52 Week High | $11.76 | $3.56 |
| Indicator | FMN | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 70.10 |
| Support Level | $11.02 | $2.14 |
| Resistance Level | $11.32 | $2.48 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 33.59 | 84.58 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.